Concourse Financial Group Securities, Inc. Eq Rx, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share
Q3 2023 Oct 30, 2023	BUY	$1.66 - $2.31 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.66 - $2.31 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.61 - $1.96 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.8 - $2.83 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$2.05 - $5.5 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.94 - $5.99 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$3.2 - $5.69 $0 - $0
Q1 2022 May 09, 2022	BUY	$2.8 - $7.39 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$5.92 - $9.98 $0 - $0

Others Institutions Holding EQRX

# of Institutions

Shares Held

67.8M

Call Options Held

Put Options Held

Ah Equity Partners Bio Iii, L.L.C. Menlo Park, CA

19.2M
Shares

$0
100.0% of portfolio
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA

17.4M
Shares

$0
60.15% of portfolio
Arboretum Ventures, Inc.

13.9M
Shares

$0
63.96% of portfolio
Ah Equity Partners Lsv I, L.L.C. Menlo Park, CA

11.4M
Shares

$0
8.42% of portfolio
Ah Equity Partners Lsv Ii, L.L.C. Menlo Park, CA

5M
Shares

$0
11.61% of portfolio

View Full List

About EQRx, Inc.

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

More about EQRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account